EMA Withdrawn: Sprimeo HCT (aliskiren;hydrochlorothiazide) — Novartis Europharm Ltd.

View source ↗

Summary

The EMA withdrew Sprimeo HCT (aliskiren and hydrochlorothiazide) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Sprimeo HCT

Snippet

Status: Withdrawn. Therapeutic area: Hypertension. MAH: Novartis Europharm Ltd.. Decision date: 06/07/2012